IRDI SORIDEC Gestion
VC Fund
Toulouse, France
IRDI SORIDEC Gestion is a portfolio management company that supports startups, SMEs, and ETIs in the greater South-West of France with equity capital at all stages of development.
- Total investments:
- 54
- Last investment:
- Lead investor:
- 24%
Last updated:
For AI agents: llms.txt
Industries IRDI SORIDEC Gestion invests in
Stages IRDI SORIDEC Gestion invests in
Countries IRDI SORIDEC Gestion invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Seed
- $1.6M–$5.8M
- Series A
- $3.7M–$13M
Investment Focus
Industry
- Software 11 (20%)
- Biotechnology 10 (19%)
- Medical 7 (13%)
- Health Care 7 (13%)
- Manufacturing 7 (13%)
Stage
- Seed 17 (31%)
- Series A 13 (24%)
- Funding Round 8 (15%)
- Venture - Series Unknown 5 (9%)
- Series B 4 (7%)
Country
- France 40 (74%)
- Brazil 1 (2%)
- Singapore 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Benedikt Timmerman
Venture Partner
|
Venture Partner | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Nepting
|
NEPTING is a company specializing in payment solutions and services with the main objective of supporting business in its evolution. Listening to its customers, it brings a skill, a culture, an innovative offer for all existing, emerging and future payment methods.NEPTING equips all types of points of acceptance with its multi-channel andmulti-vendor electronic payment system and its secure solutions in compliance with the standards in force. It is distinguished by its ability to give its customers the many advantages of a single and homogeneous offer for all its sales channels: mPOS, Retail, TPE, Automate, e-commerce ... | Private Equity / Jun 11, 2026 | |
Donecle
|
Donecle offers an ultra-fast inspection solution based on drones. | $11.8M / Venture - Series Unknown / Apr 15, 2026 | |
DiappyMed
|
DiappyMed specializes in developing platforms to calculate insulin dosages. | $5.8M / Seed / Mar 22, 2026 | |
Sim&Cure
|
Sim&Cure is the first company to be cleared to market a patient-based simulation model for aneurysm treatment that allows prediction of the deployment of medical devices (flow diverter, intrasaccular device, laser-cuter stent). Sim&Size® simulates each size and type of device according to the patient’s unique anatomy in order to provideessential information prior to the choice of sizing. | $11.6M / Series A / Nov 28, 2025 | |
Infinite Orbits
|
Infinite Orbits is a satellite servicing company that focuses on satellite maintenance, orbit correction, and de-orbiting services. | $46.2M / Series B / Nov 10, 2025 | |
Greenphage
|
Greenphage develops bacteriophage-based methods to address bacterial infections and contaminations in human, animal, and plant health. It uses bacteriophages to create alternatives to antibacterial treatments. The company conducts laboratory research on phage studies, molecular virology, and microbiology. It also works with research institutions tosupport its phage therapy efforts. | $2.2M / Seed / Jul 10, 2025 | |
bYoRNA
|
bYoRNA is a French biotechnology company specializing in the cost-efficient, scalable bioproduction of high-quality therapeutic messenger RNA (mRNA) using engineered eukaryotic cells, particularly recombinant yeast. Their disruptive platform enables the production of long, humanized mRNA with lower immunogenicity and higher integrity compared totraditional in vitro enzymatic synthesis. This technology aims to mass produce mRNA for gene therapies, cancer vaccines, and infectious disease vaccines at a fraction of current costs, making mRNA therapeutics more accessible globally. | $1.8M / Pre-Seed / Jul 08, 2025 | |
FEEDAE
|
Feedae uses AI-augmented dialog analysis to boost sales and customer service teams' performance. | $1.7M / Seed / Mar 31, 2025 | |
Matchers
|
Matchers specialize in providing organization training courses and programs related to administration and management. | $1.3M / Venture - Series Unknown / Dec 19, 2024 | |
Keysom
|
Develops RISC V based processor architectures that are automatically built from the application source code and dynamically reconfigurable. | $4.4M / Seed / Oct 08, 2024 | |
| See all 54 investments → | |||
Co-Investors
Bpifrance
15 deals together
Sofilaro
8 deals together
IXO Private Equity
6 deals together
Eurazeo
5 deals together
European Innovation Council and SMEs Executive Agency
4 deals together
M Capital Partners
4 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does IRDI SORIDEC Gestion invest in?
IRDI SORIDEC Gestion invests primarily in Software, Biotechnology and Medical startups, most often at Seed and Series A stage. Most of the 54 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is IRDI SORIDEC Gestion's check size?
IRDI SORIDEC Gestion typically joins rounds of $1.6M–$5.8M at Seed and $3.7M–$13M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds IRDI SORIDEC Gestion participates in.
How do I contact IRDI SORIDEC Gestion?
Public channels for IRDI SORIDEC Gestion include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at IRDI SORIDEC Gestion?
The team at IRDI SORIDEC Gestion includes Benedikt Timmerman (Venture Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
